Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This post hoc analysis included patients with acute leukemia who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine and Ruijin Hospital Shanghai Jiaotong University School of Medicine. Patients and their donors were assessed for eligibility to join this study. The inclusion criteria were: (1) age ≥ 5 years; (2) diagnosis of acute leukemia including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia; (3) patients attained complete remission (CR) and achieved full engraftment with 100% donor chimerism following allo-HSCT; (4) telomere testing was conducted on peripheral leukocytes of donors before granulocyte colony-stimulating factor (G-CSF) mobilization, and the results were obtained. Written informed consent was obtained from all included patients and their donors, and the study was conducted in compliance with the Declaration of Helsinki. Ethical approval was approved by the ethics review committee of the First Affiliated Hospital of Zhejiang University School of Medicine.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Donors aged 40 years or older |
| ||
| Donors aged < 40 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention, observation study | Other | No intervention, observation study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | The duration from transplant until death resulted from any cause. | From date of transplantuntil the date of death from any cause, assessed up to 60 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Relapse-free survival | The time from transplant until death or relapse. | From date of transplant until the date of relapse or death from any cause, assessed up to 60 months. |
| Cumulative incidence of relapse |
Not provided
Inclusion Criteria:
Exclusion Criteria
Not provided
Not provided
This study aims to investigate the influence of donor blood telomere length on recipients' clinical outcomes post-allogeneic hematopoietic stem cell transplant.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| He Huang, PhD&MD | Contact | +86 13605714822 | huanghe@zju.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University | Recruiting | Hangzhou | Zhejiang | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The time interval between the transplant and the occurrence of relapse.
| From date of transplant until the date of relapse, assessed up to 60 months. |